TNXP - Tonix Pharmaceuticals Inc. Market Cap to Sales Volume
Tonix Pharmaceuticals (TNXP) shareholder stakes are being diluted due to regular secondary offerings to fund project development. The shift in the P/S multiple reflects the business valuation dynamics, where 1.30 shapes the current metric. The company's survival depends on FDA verdicts in the CNS field, while overall success is based on scientific breakthroughs in treating infections, ignoring standard economic cycles.
Tonix Pharmaceuticals Holding Corp. (TNXP) - metric breakdowns and financial figures
- share price and consensus valuation forecast:
- market capitalization statistics:
- book capitalization information:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Coefficient Tonix Pharmaceuticals|TNXP - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Ratio Tonix Pharmaceuticals Holding Corp.|TNXP - Company Total Debt|Debt to Net Assets Ratio Tonix Pharmaceuticals|TNXP - Company Long-Term Debt|Current Liabilities Tonix Pharmaceuticals|Intermediate Coverage Ratio tonixpharma.com
- earnings and multiples data:
TNXP - Net Profit|Projected Future Earnings Tonix Pharmaceuticals|TNXP - Price to Earnings Ratio|Future Price to Earnings Multiple Tonix Pharmaceuticals Holding|TNXP - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Tonix Pharmaceuticals Holding|TNXP - Operating profit EBITDA|Net earnings per share (EPS TTM) Tonix Pharmaceuticals|TNXP - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months tonixpharma.com|TNXP - Earnings growth in current year|Expected net earnings per share growth next year Tonix Pharmaceuticals
- total revenue and sales volume data:
Summary company analytics:Tonix Pharma, TNXP
The P/S ratio compares market capitalization to actual sales volume, allowing for an assessment of the premium paid for future earnings. By analyzing the P/S ratio dynamics of Tonix Pharmaceuticals (TNXP), an investor can determine whether market expectations are justified within the biopharmaceutical context, where low mass-production costs following expensive clinical trials ensure high business scalability.
Competitors of Tonix Pharmaceuticals
HLN (Haleon) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Kenvue Inc KVUE|Verona Pharma Corp - Price-to-Revenue Ratio|MENS: Market Cap to Revenue|Price-to-Revenue Coefficient Ligand Pharmaceuticals LGND|Amneal Pharmaceuticals Inc (AMRX) - Price-to-Revenue Ratio|Perrigo Company PLC - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio alvotech.com|P/S Multiple Liquidia Technologies|Price-to-Revenue Ratio Galapagos Genomics (GLPG)|ANIP: Price-to-Sales Ratio|P/S Multiple MNKD (MannKind Corp)|Price-to-Revenue Coefficient Amphastar (AMPH)|PCRX: Market Cap to Revenue|SPRY - P/S Multiple|Theravance Biopharma, Inc. (TBPH) - Price-to-Revenue Ratio|AQST (Aquestive Therapeutics) - Price-to-Revenue Ratio|SCPH (scpharmaceuticals.com) - P/S Multiple|TECX: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue SXTC (SXT Pharmaceuticals)|EPRX: Price-to-Sales Ratio|BioHarvest Sciences - Market Cap to Revenue|EXOZ: Market Cap to Revenue Ratio|ORMP - Price-to-Revenue Ratio|ENTX: Price-to-Revenue Ratio|HYFT: P/S Multiple|Market Cap to Revenue ABVC BioPharma Inc|CPIX (Cumberland Corp) - P/S Multiple|P/S Multiple quantumbiopharma.com|P/S Multiple FGEN|Market Cap to Revenue Telomir Pharmaceuticals, Inc. TELO|P/S Multiple RANI (Rani Therapeutics)|SNYR (Synergy CHC Corp) - Price-to-Sales Ratio|RLYB: Market Cap to Revenue|lexariabioscience.com (LEXX) - Market Cap to Revenue|Pulmatrix Inc (PULM) - Price-to-Revenue Ratio|PTHL: Market Cap to Sales Volume|APM (Aptorum Group Ltd) - P/S Multiple|Lyra Therapeutics Inc (LYRA) - Price-to-Revenue Coefficient|P/S Multiple IBO|Market Cap to Sales Volume TNFA|cbdMD, Inc. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio PRFX|Altamira Therapeutics Ltd. - P/S Multiple|LIPO: Price-to-Revenue Ratio|OPTN: P/S Multiple|Price-to-Sales Ratio PIRS (Pieris Pharmaceuticals)|PROC (Procaps) - P/S Multiple|PTPI (Petros Pharmaceuticals Inc) - Market Cap to Sales Volume|P/S Multiple QLI|SLRN - Price to Sales|P/S Multiple TFFP (TFF Pharmaceuticals, Inc)
